Head & Neck Cancers

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.

The FDA has granted a priority review to the oral multiple tyrosine kinase receptor inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), according to the manufacturer of the drug, Eisai.

Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing over the last few decades, mostly due to HPV, which is now associated with the majority of newly diagnosed cases of OPSCC.

A growing understanding of the biological pathways at work in the development of oral mucositis in patients treated with cytotoxic cancer therapies has helped spur interest in steering symptom management away from "institutional folklore" rinses and anecdotal approaches toward evidence-based strategies

Anthony J. Cmelak, MD, professor, Radiation Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of ECOG1308, a study that evaluated reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response to induction chemotherapy.